Valacyclovir overdosage: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
Line 6: Line 6:


Caution should be exercised to prevent inadvertent overdose [see Use in Specific Populations (8.5, 8.6)]. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of [[acute renal failure]] and [[anuria]], the patient may benefit from [[hemodialysis]] until renal function is restored [see Dosage and Administration (2.4)].<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf | publisher = |date = | accessdate = }}</ref>
Caution should be exercised to prevent inadvertent overdose [see Use in Specific Populations (8.5, 8.6)]. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of [[acute renal failure]] and [[anuria]], the patient may benefit from [[hemodialysis]] until renal function is restored [see Dosage and Administration (2.4)].<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf | publisher = |date = | accessdate = }}</ref>


==References==
==References==

Latest revision as of 23:24, 2 January 2014

Valacyclovir
VALTREX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Overdosage

Caution should be exercised to prevent inadvertent overdose [see Use in Specific Populations (8.5, 8.6)]. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored [see Dosage and Administration (2.4)].[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.